Metabolic Genetics

Long-Term Monitoring and Future Research

At a Glance

Long-term care for Free Sialic Acid Storage Disease is individualized and may include neurological exams, brain MRI, eye and hearing checks, and heart monitoring, along with symptom-focused and palliative support. No approved therapy reverses the genetic cause; gene-editing and drug approaches are still being tested in labs.

Managing Free Sialic Acid Storage Disease (FSASD) is a lifelong commitment to monitoring and supportive care. Because there are currently no approved therapies that can reverse the underlying genetic cause, the goal of long-term care is to identify and manage symptoms early to maintain the best possible quality of life ^[1]^[2].

Recommended Surveillance Schedule

While your medical team will tailor a plan to your specific needs, the following are illustrative examples of what an individualized monitoring plan might include for managing the multisystem impacts of FSASD ^[3]^[1]:

Specialty	Common Frequency	Focus Areas
Metabolic Genetics	Individualized	Reviewing growth, diet, and potentially tracking biomarkers like urine and plasma free sialic acid. (Note: These biomarkers are useful for diagnosis, but are not universally validated as reliable ways to track day-to-day disease progression) ^[3]^[4].
Pediatric Neurology	Individualized	Monitoring for ataxia, spasticity, and any new or changing seizures ^[1]^[5].
Brain MRI	As needed	Used to baseline brain structure (e.g., myelination and corpus callosum) and repeat if symptoms change significantly ^[3]^[6].
Ophthalmology	Individualized	Screening for myopia (nearsightedness), exotropia (eye turning), and optic atrophy ^[3]^[7].
Audiology	Individualized	Monitoring for hearing loss or abnormal auditory brainstem responses (ABR) ^[3].
Cardiology	As directed (ISSD)	For children with the severe infantile form, screening for cardiomegaly (enlarged heart) is often necessary ^[7]^[8].

The Future of Research: Experimental Approaches

Scientists are actively working on new ways to treat FSASD at the cellular level. While these are currently in the preclinical stage—meaning they are being tested in labs and on animal models rather than in humans, have no established human safety or efficacy data, and cannot be obtained outside of regulated research studies—they represent the “frontier” of FSASD research:

Adenine Base Editing (ABE): This is a highly precise form of “gene editing.” In laboratory tests using skin cells (fibroblasts) from patients with the common R39C genetic variant, ABE was able to correct the error and significantly reduce the buildup of free sialic acid inside the cells ^[9].
Sialin Ligand Compounds (LSP12-3129): This experimental compound (also known as compound 45) is being studied as a potential “pharmacological chaperone.” In lab settings, it helped “rescue” the broken sialin protein, helping it move correctly within the cell ^[10].
Natural History Studies: Because FSASD is so rare, one of the most important areas of research is simply documenting how the disease progresses in different people. Participating in these studies helps researchers identify “endpoints” (measurable changes) for future clinical trials ^[1]^[11].

Palliative Care and Quality of Life

Palliative care is not just for the end of life; it is a specialized layer of support focused on relieving the symptoms and stress of a serious illness ^[12]. For families managing FSASD at any stage, a palliative team can provide:

Symptom Management: Expertise in treating complex issues like severe muscle stiffness (spasticity), pain, or sleep disturbances that standard treatments may not fully address ^[13]^[14].
Advanced Care Planning: Helping families make difficult decisions about feeding tubes, breathing support, or hospitalizations before a crisis occurs ^[12].
Emotional Support: Providing a dedicated space to discuss the impact of the disease on siblings, parents, and the family’s overall well-being ^[15]^[16].

The road with FSASD is challenging, but you do not have to walk it alone. Ongoing collaboration between families, researchers, and specialized medical teams is essential for improving care today and finding the treatments of tomorrow ^[1]^[17].

Common questions in this guide

What does long-term monitoring for FSASD involve?

A monitoring plan is individualized and may include metabolic genetics, pediatric neurology, brain MRI, eye exams, hearing tests, and cardiology when the severe infantile form is present. Clinicians may track movement, muscle stiffness, seizures, vision, hearing, and heart size.

How often should a person with FSASD have MRI, eye, and hearing checks?

There is no single schedule for everyone with FSASD. Brain MRI may be repeated when symptoms change significantly, while eye and hearing checks are scheduled according to the person’s development, symptoms, and clinical needs.

Can urine or plasma free sialic acid show whether FSASD is getting worse?

Urine and plasma free sialic acid can support diagnosis, but these biomarkers are not universally validated as reliable measures of day-to-day disease progression. Ask the metabolic genetics team whether repeat testing is useful for your specific care plan.

Are natural history studies or clinical trials available for FSASD?

Natural history studies document how FSASD changes over time and help researchers identify measurable endpoints for future clinical trials. Availability and eligibility vary by location, so a specialist or research center can help identify appropriate studies.

What experimental treatments are being studied for FSASD?

Lab-stage research includes adenine base editing, which corrected the common R39C variant in patient skin cells, and the sialin ligand compound LSP12-3129, which helped the sialin protein move correctly in laboratory studies. These approaches have no established human safety or effectiveness and are not available outside regulated research studies.

Can palliative care help someone with FSASD before the end of life?

Yes. Palliative care can be added at any stage to help relieve symptoms such as muscle stiffness, pain, and sleep problems, while also supporting care planning and the emotional well-being of the patient and family.

When should we contact the FSASD care team sooner than planned?

Contact the care team about new or changing seizures, a significant change in movement or communication, worsening stiffness, new pain or sleep problems, or another major change in symptoms. The team can explain which changes require an urgent call or emergency care.

Get notified when new evidence is published on Free sialic acid storage disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (17)

1
Free sialic acid storage disorder: Progress and promise.
Huizing M, Hackbarth ME, Adams DR, et al.
Neuroscience letters 2021; (755()):135896 doi:10.1016/j.neulet.2021.135896.
PMID: 33862140
2
Sialic acid-Retaled disorders: Advances in pathophysiology, diagnostic challenges, and differentiating mimics.
Assiri I, Fdil N
Clinica chimica acta; international journal of clinical chemistry 2026; (579()):120620 doi:10.1016/j.cca.2025.120620.
PMID: 40972914
3
Clinical and Genetic Characteristics of Free Sialic Acid Storage Disorder.
Wolfenson Z, Grois G, Hailemeskel RF, et al.
Journal of inherited metabolic disease 2026; (49(2)):e70148 doi:10.1002/jimd.70148.
PMID: 41879269
4
A cross-sectional quantitative analysis of the natural history of free sialic acid storage disease-an ultra-orphan multisystemic lysosomal storage disorder.
Zielonka M, Garbade SF, Kölker S, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(2)):347-352 doi:10.1038/s41436-018-0051-3.
PMID: 29875421
5
Longitudinal Characterization of the Clinical Course of Intermediate-Severe Salla Disease.
Chapleau A, Mirchi A, Tran LT, et al.
Pediatric neurology 2023; (148()):133-137 doi:10.1016/j.pediatrneurol.2023.08.013.
PMID: 37713976
6
A New Patient With Intermediate Severe Salla Disease With Hypomyelination: A Literature Review for Salla Disease.
Barmherzig R, Bullivant G, Cordeiro D, et al.
Pediatric neurology 2017; (74()):87-91.e2 doi:10.1016/j.pediatrneurol.2017.05.022.
PMID: 28662915
7
A novel SLC17A5 variant in infantile sialic acid storage disease with hyporegenerative anemia: Neuroimaging insights and literature review.
Cappozzo F, Severino M, Gennaro E, et al.
Molecular genetics and metabolism reports 2025; (45()):101284 doi:10.1016/j.ymgmr.2025.101284.
PMID: 41459346
8
Biochemical and molecular analyses of infantile sialic acid storage disease in a patient with nonimmune hydrops fetalis.
Kang E, Kim YM, Heo SH, et al.
Clinica chimica acta; international journal of clinical chemistry 2018; (482()):199-202 doi:10.1016/j.cca.2018.04.016.
PMID: 29654786
9
Base editing corrects the common Salla disease SLC17A5 c.115C>T variant.
Harb JF, Christensen CL, Kan SH, et al.
Molecular therapy. Nucleic acids 2023; (34()):102022 doi:10.1016/j.omtn.2023.08.024.
PMID: 37727271
10
Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
Dubois L, Pietrancosta N, Cabaye A, et al.
Journal of medicinal chemistry 2020; (63(15)):8231-8249 doi:10.1021/acs.jmedchem.9b02119.
PMID: 32608236
11
Study design challenges and strategies in clinical trials for rare diseases: Lessons learned from pantothenate kinase-associated neurodegeneration.
Videnovic A, Pfeiffer HCV, Tylki-Szymańska A, et al.
Frontiers in neurology 2023; (14()):1098454 doi:10.3389/fneur.2023.1098454.
PMID: 36970548
12
Clinical characteristics of adult patients with inborn errors of metabolism in Spain: A review of 500 cases from university hospitals.
Pérez-López J, Ceberio-Hualde L, García-Morillo JS, et al.
Molecular genetics and metabolism reports 2017; (10()):92-95 doi:10.1016/j.ymgmr.2017.01.011.
PMID: 28224082
13
Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration.
Marshall RD, Collins A, Escolar ML, et al.
Orphanet journal of rare diseases 2019; (14(1)):174 doi:10.1186/s13023-019-1142-1.
PMID: 31300018
14
Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration.
Klopstock T, Videnovic A, Bischoff AT, et al.
Movement disorders : official journal of the Movement Disorder Society 2021; (36(6)):1342-1352 doi:10.1002/mds.28392.
PMID: 33200489
15
A systematic review and integrative sequential explanatory narrative synthesis: The psychosocial impact of parenting a child with a lysosomal storage disorder.
Hassall S, Smith DM, Rust S, Wittkowski A
Journal of inherited metabolic disease 2022; (45(3)):406-416 doi:10.1002/jimd.12482.
PMID: 35124835
16
"We are ambassadors, we are advocates": rare disease patient advocacy groups as knowledge brokers across health and social systems-a qualitative study from Poland.
Domaradzki J
Frontiers in public health 2026; (14()):1743598 doi:10.3389/fpubh.2026.1743598.
PMID: 41835439
17
Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses.
Shapiro EG, Escolar ML, Delaney KA, Mitchell JJ
Molecular genetics and metabolism 2017; (122S()):8-16 doi:10.1016/j.ymgme.2017.09.007.
PMID: 29128371

This page is for informational purposes only and does not constitute medical advice. Monitoring, palliative care, and research decisions for Free Sialic Acid Storage Disease should be individualized with your medical team.